Monoclonal antibody treatments for multiple sclerosis

被引：16

作者：

Rose, John W. ^{[1
]}

Foley, John ^{[1
]}

Carlson, Noel ^{[1
]}

机构：

[1] VA Salt Lake City Hlth Care Syst, Neurovirol Res Lab, Salt Lake City, UT USA

来源：

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS | 2008年 / 8卷 / 05期

关键词：

D O I：

10.1007/s11910-008-0065-3

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Monoclonal antibodies (MAbs) may have great potential as therapies for autoimmune diseases. Their development as treatments for multiple sclerosis (MS) is promising. Partially effective immunomodulatory therapies have been helpful for many MS patients; however, for patients failing these immunomodulatory treatments, MAbs are an important new treatment option. Currently, MAbs are approved by the US Food and Drug Administration for treatment of many conditions, including autoimmune diseases. Four MAbs that have been investigated as potential treatments for MS are reviewed in this article. Of these MAbs, natalizumab is approved for treatment of MS. The other three MAbs (alemtuzumab, rituximab, and daclizumab) are all promising therapies in development for treatment of MS. Adverse effects are relatively mild for these MAbs; however, care in administration and management of these agents is emphasized. Overall, these MAb therapies have great promise in the treatment of MS.

引用

页码：419 / 426

页数：8

共 63 条

[1] The potential utility of B cell-directed biologic therapy in autoimmune diseases [J].

Arkfeld, D. G. .

RHEUMATOLOGY INTERNATIONAL, 2008, 28 (03) :205-215

[2] Natalizumab reduces visual loss in patients with relapsing multiple sclerosis [J].

Balcer, L. J. ;

Galetta, S. L. ;

Calabresi, P. A. ;

Confavreux, C. ;

Giovannoni, G. ;

Havrdova, E. ;

Hutchinson, M. ;

Kappos, L. ;

Lublin, F. D. ;

Miller, D. H. ;

O'Connor, P. W. ;

Phillips, J. T. ;

Polman, C. H. ;

Radue, E.-W. ;

Rudick, R. A. ;

Stuart, W. H. ;

Wajgt, A. ;

Weinstock-Guttman, B. ;

Wynn, D. R. ;

Lynn, F. ;

Panzara, M. A. .

NEUROLOGY, 2007, 68 (16) :1299-1304

[3]

BARONE MA, 1996, HARRIET LANE HDB, P8

[4]

Becker Barbara, 1994, Goethe Yearbook, V7, P1

[5] Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis [J].

Bennett, JL .

NEUROLOGICAL RESEARCH, 2006, 28 (03) :291-298

[6] Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis [J].

Bielekova, B ;

Catalfamo, M ;

Reichert-Scrivner, S ;

Packer, A ;

Cerna, M ;

Waldmann, TA ;

McFarland, H ;

Henkart, PA ;

Martin, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) :5941-5946

[7] Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β [J].

Bielekova, B ;

Richert, N ;

Howard, T ;

Blevins, G ;

Markovic-Plese, S ;

McCartin, J ;

Würfel, J ;

Ohayon, J ;

Waidmann, TA ;

McFarland, HF ;

Martin, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (23) :8705-8708

[8]

BUTTMAN P, 2008, EXPERT REV NEUROTHER, V8, P433

[9] The incidence and significance of anti-natalizumab antibodies -: Results from AFFIRM and SENTINEL [J].

Calabresi, P. A. ;

Giovannoni, G. ;

Confavreux, C. ;

Galetta, S. L. ;

Havrdova, E. ;

Hutchinson, M. ;

Kappos, L. ;

Miller, D. H. ;

O'Connor, P. W. ;

Phillips, J. T. ;

Polman, C. H. ;

Radue, E. -W. ;

Rudick, R. A. ;

Stuart, W. H. ;

Lublin, F. D. ;

Wajgt, A. ;

Weinstock-Guttman, B. ;

Wynn, D. R. ;

Lynn, F. ;

Panzara, M. A. ;

Macdonell, R. ;

Hughes, A. ;

Taylor, I. ;

Lee, Y. C. ;

Ma, H. ;

King, J. ;

Kilpatrick, T. ;

Butzkueven, H. ;

Marriott, M. ;

Pollard, J. ;

Spring, P. ;

Spies, J. ;

Barnett, M. ;

Dehaene, I. ;

Vanopdenbosch, L. ;

D'Hooghe, M. ;

Van Zandijcke, M. ;

Derijck, O. ;

Seeldrayers, P. ;

Jacquy, J. ;

Piette, T. ;

De Cock, C. ;

Medaer, R. ;

Soors, P. ;

Vanroose, E. ;

Vanderhoven, L. ;

Nagels, G. ;

Dubois, B. ;

Deville, M. -C. ;

D'Haene, R. .

NEUROLOGY, 2007, 69 (14) :1391-1403

[10]

COLES A, 2007, 23 C EUR COMM TREATM

← 1 2 3 4 5 6 7 →